Prostate News Archive
09-May-2008
Study shows prostate cancer gene 3 (PCA3) correlates with severity of prostate cancer (News-Medical-Net)
A study published in the May 2008 issue of the peer-reviewed Journal of Urology demonstrates that the prostate cancer gene 3 (PCA3) can be used to detect and stratify stage and grade of prostate cancer. Cleveland BioLabs Completes Recruitment For Phase II Hormone-Refractory Prostate Cancer Trial (Medical News Today)
Cleveland BioLabs, Inc. (NASDAQ: CBLI), announced that it has fully enrolled its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer. This open label trial is evaluating the safety and efficacy of Curaxin CBLC102 for use in treating patients with hormone-refractory metastatic prostate cancer. Firm rolls out machine to battle prostate cancer (The Union)
The battle against prostate cancer has been taken to new heights, according to a Grass Valley high-tech firm that developed a machine for the fight. New Herbal Supplement Promotes Healthy Prostate (Carteret County News-Times)
(ARA) - If you're a man who suffers from any of these symptoms -- waking up several times a night to use the bathroom, difficulty starting your stream, poor urine flow and volume or erectile dysfunction -- it may be a sign of an even bigger problem: an enlarged prostate. Prostate Cancer Breakthrough Receives FDA Clearance (Business Wire via Yahoo! Finance)
GRASS VALLEY, Calif.----A new imaging device, ei-Nav/Artemis?, now officially cleared by the U.S. Food and Drug Administration , offers urologists breakthrough technology that will significantly help in the fight against prostate cancer.
Back to Prostate News Archive
